Lasa Supergenerics share news, announcements and annual reports
NSE: LASABSE: 540702Pharmaceuticals & BiotechnologySmall Cap
Lasa Supergenerics Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2017
Last close ₹4.67down ₹0.24 (4.89%)BSE ₹5.03
Share price at the NSE close on 26 Oct 2026. Previous close ₹4.91.
26 Oct: open ₹4.86, high ₹4.86, low ₹4.67
52-week range of traded prices to 26 Oct 2026
₹4.67Low, 26 Oct 2026₹12.48High, 5 Jan 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹23 Cr3,595th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.47
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −24.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −24.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 42,091
Lasa Supergenerics disputes and clarifications
37 filed, newest first.
Sep 2026
2 Sep · Legal
Exchange has sought clarification from Lasa Supergenerics Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.2 Sep · Legal
Clarification - Financial Results
Mar 2026
11 Mar · Legal
Exchange has sought clarification from Lasa Supergenerics Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI. The response of the Company is awaited.11 Mar · Legal
Clarification - Financial Results
Jan 2024
Dec 2023
14 Dec · Legal
Exchange has sought clarification from Lasa Supergenerics Limited for the quarter ended 30-Sep-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.14 Dec · Legal
Clarification - Financial Results
Apr 2022
7 Apr · Legal
The exchange asked on 6 Apr 2022
6 Apr · Legal
Exchange has sought clarification from Lasa Supergenerics Ltd on April 6, 2022 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Oct 2021
19 Oct · Legal
Exchange has sought clarification from Lasa Supergenerics Limited with respect to announcement dated 18-Oct-2021, regarding Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify following: 1. Expected quantum of loss/damage caused;The response of the Company is awaited.19 Oct · Legal
Clarification
Aug 2021
23 Aug · Legal
Exchange has sought clarification from Lasa Supergenerics Limited with respect to announcement dated 21-Aug-2021, regarding appointment of Mr. Shivanand hedge at its board meeting held on August 21, 2021. On basis of above the Company is required to clarify following: 1. Confirmation in compliance with SEBI Letter dated June 14, 2018 read alongwith NSE Circular dated June 20, 2018. The response of the Company is awaited.23 Aug · Legal
Clarification
Jul 2021
26 Jul · Legal
Exchange has sought clarification from Lasa Supergenerics Limited with respect to announcement dated 23-Jul-2021, regarding strikes/lockouts/disturbances. On basis of above the Company is required to clarify following: 1. Whether loss/damage covered by insurance or not including amount;2. Expected quantum of loss/damage caused;The response of the Company is awaited.26 Jul · Legal
Clarification
Jun 2021
23 Jun · Legal
Exchange has sought clarification from Lasa Supergenerics Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.23 Jun · Legal
Clarification - Financial Results
Jun 2020
Jan 2020
10 Jan · Legal
Exchange has sought clarification from Lasa Supergenerics Ltd on 10th January, 2020 with reference to significant movement in price, in order to ensure that investors have latest ....10 Jan · Legal
The exchange asked on 10 Jan 2020
Dec 2018
Jul 2018
May 2018
29 May · Legal
Exchange has sought clarification from Lasa Supergenerics Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of profit and loss not submitted -2. Standalone Balance sheet statement not submitted -3. Financial results not signed by authorized signatory/ies -4. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.29 May · Legal
Clarification - Financial Results8 May · Legal
Exchange had sought clarification from Lasa Supergenerics Limited with respect to announcement dated 27-Apr-2018, regarding " Lasa Supergenerics Limited has informed the Exchange regarding 'Intimation regarding a fire incident in Mahad MIDC very close to company s Mahad Unit.'.".On basis of above the Company is required to clarify following:1. Whether loss/damage covered by insurance or not including amount; 2. Expected quantum of loss/damage caused; The response of the Company is below: No loss to life or any injury at Lasa Unit All hard assets intact with no major impact Assets covered under appropriate insurance8 May · Legal
Reply to Clarification Sought
Apr 2018
30 Apr · Legal
Exchange has sought clarification from Lasa Supergenerics Limited with respect to announcement dated 27-Apr-2018, regarding " Lasa Supergenerics Limited has informed the Exchange regarding 'Intimation regarding a fire incident in Mahad MIDC very close to company's Mahad Unit.'.". On basis of above the Company is required to clarify following: 1. Whether loss/damage covered by insurance or not including amount; 2. Expected quantum of loss/damage caused; The response of the Company is awaited.30 Apr · Legal
Clarification
Feb 2018
14 Feb · Legal
Exchange has sought clarification from Lasa Supergenerics Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Reconciliation of profit and loss not submitted. The response of the Company is awaited.14 Feb · Legal
Clarification - Financial Results